engleski

Efficacy and tolerability of fluvoxamine in outpatients with anxiety disorders

Prospective, three months study of efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders. The subjects were the patients older than 18 years of age, previously without therapy of treated with other psychopharmacological treatment, with diagnosis of Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder). Clinical efficacy was evaluated with Hamilton Anxiety Rating Scale HAM-A and Clinical Global Impression scales at baseline visit, after one month and after three months of fluvoxamine therapy. Side effects were recorded during the therapy. Aim of the study: Evaluation of the efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder). Inclusion criteria: Female and male outpatients older than 18 years o age treated in Psychiatry Clinic Clinical Hospital Center Split, previously without therapy or treated with other psychopharmacological treatment, to which one of the following Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder) was diagnosed. Exclusion criteria: - Hypersensitivity to fluvoxamine - Pregnancy and lactation - Hepatic or kidney insufficiency - Unstable epilepsy - Discontinuation of the treatment with irreversible monoamine oxidase inhibitors less than 14 days prior introduction of fluvoxamine therapy - Discontinuation of moclobemide therapy less than one day prior introduction of fluvoxamine therapy. Statistical methods: Descriptive statistic was used for the analysis of demographic data and incidence of adverse events. Repeated Measures Analysis of Variance was used for data analysis (Statistical software SPSS). Statistical significance was defined as p≤0, 05.

fluvoxamine; anxiety disorders

nije evidentirano